PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile an area-per-cent purity with an impurity table?

Asked 11 Apr 2024Modified 2.0 years agoViewed 19k times
2

The method section is present, which is unusual enough that I want to make use of it.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

How many significant figures are actually justified here?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
shareeditfollowflag
OK
askedoona_kekkonen16k1811 Apr 2024
3Two of us worked through this independently and arrived here, so it is at least reproducible. – Dr_Signe_Baldursdottir 21 days ago
2Worth adding that the method section is where the answer usually is. – juan_esquivel 9 months ago
add a comment

4 Answers

Accepted answer first, then by votes
110

Accepted answer

More usefully, the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
MF
answered · acceptedmeniscus_film34k383 Aug 2024
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
99

It helps to be literal here: read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Stated carefully, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
RC
answeredRP_C1885k15823 Jul 2024
4This is the answer I was looking for three months ago. – leah_ferrers 10 months ago
5The arithmetic checks out. I ran the same numbers and got the same result. – bufferline42 44 days ago
add a comment
49

More usefully, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Put another way, detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
C8
answeredcoldpack_8837k381 Jul 2024
6This is the answer I was looking for three months ago. – Dr_Rosalind_Achebe 4 months ago
5The arithmetic checks out. I ran the same numbers and got the same result. – bea_castellanos 2 months ago
add a comment
39

It helps to be literal here: reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
MI
answeredmateo_iglesias16k2712 Jul 2024
3Worth adding that the method section is where the answer usually is. – aine_mulcahy 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.